Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Oncology

The Modern Roadmap for BPDCN Treatment

At a Glance

The modern treatment roadmap for BPDCN involves three main steps: induction with targeted therapies like tagraxofusp to clear the cancer, intrathecal therapy to protect the brain, and consolidation with an allogeneic stem cell transplant for eligible patients to achieve long-term remission.

The treatment landscape for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) has transformed in recent years. While it remains an aggressive disease, there is now a structured, multi-step roadmap designed to achieve and maintain remission. The strategy focuses on clearing the cancer from the blood, skin, and nervous system, then reinforcing that “clearance” with a long-term solution [1][2].

Step 1: Induction (Clearing the Cancer)

The first goal of treatment is induction, which aims to put the disease into Complete Remission (CR). This means no detectable cancer cells remain in the blood, bone marrow, or skin [1].

  • Targeted Therapy (Tagraxofusp): This is often the first-line choice today. Tagraxofusp-erzs is a “guided missile” drug [3]. It consists of a protein that binds to the CD123 marker on BPDCN cells, carrying a payload of a modified diphtheria toxin directly into the cancer cell. This is a safely engineered protein designed specifically to attack cancer cells and cannot give you the disease [4]. Tagraxofusp is typically given as a daily intravenous (IV) infusion for 5 days in a row, with the cycle repeating every 21 days [3][2].
  • Intensive Chemotherapy: For some patients, doctors may use intensive multi-drug regimens originally designed for leukemia, such as Hyper-CVAD. These are powerful but can be harder on the body than targeted therapies [5][6].

Step 2: CNS Prophylaxis (Protecting the Brain)

BPDCN is known for its ability to “hide” in the Central Nervous System (CNS)—the fluid surrounding the brain and spinal cord—where standard intravenous treatments may not reach well [7].

  • To prevent a relapse in the brain, doctors use CNS prophylaxis, which involves intrathecal therapy [8].
  • During this procedure, chemotherapy is delivered directly into the spinal fluid via a lumbar puncture (spinal tap) [7][9]. This is a critical step even if you have no neurological symptoms.

Step 3: Consolidation (The Ultimate Goal)

Because BPDCN has a high risk of returning, achieving remission is only half the battle. For patients who are healthy enough, the gold standard for long-term survival is an Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) [10][11].

Term Definition
First Complete Remission (CR1) The first time your tests show no evidence of cancer after induction [11].
Allogeneic Using healthy stem cells from a donor (like a sibling or a matched unrelated donor) [12].
Consolidation Treatment given once you are in remission to “mop up” any remaining invisible cells [1].

Statistics show that patients who receive a transplant while in CR1 have significantly better outcomes [11]. For eligible patients, an allo-HSCT offers the highest established probability of a long-term cure [13].

If You Are Not a Candidate for Transplant

Because the median age for a BPDCN diagnosis is between 65 and 70, many patients may not be eligible for an intensive stem cell transplant due to age or other health conditions [14]. If you are transplant-ineligible, there is still a clear plan. Your doctors will continue with a maintenance phase—often continuing tagraxofusp or utilizing alternative combinations like venetoclax and hypomethylating agents to manage the disease long-term and focus on your quality of life [15].

Common questions in this guide

What is the first treatment for BPDCN?
The first step is induction therapy, which aims to clear the cancer from your blood, bone marrow, and skin to achieve complete remission. Doctors often use a targeted therapy drug called tagraxofusp, though intensive chemotherapy may be recommended for some patients.
Why do I need chemotherapy in my spinal fluid?
BPDCN can hide in the central nervous system where standard intravenous drugs cannot easily reach. Doctors use intrathecal therapy, delivering chemotherapy directly into the spinal fluid, to protect your brain and prevent the cancer from returning there.
Am I a candidate for a stem cell transplant?
A stem cell transplant is the gold standard for long-term survival, but it requires a patient to be healthy enough for the intensive procedure. Your doctor will evaluate your age, overall health, and whether you have achieved a complete remission to determine if you are eligible.
What happens if I cannot have a stem cell transplant for BPDCN?
If you are not eligible for a transplant, your care team will transition you to a maintenance phase. This often involves continuing targeted therapies to manage the disease long-term while focusing on your overall quality of life.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I a better candidate for tagraxofusp or intensive chemotherapy as my first treatment?
  2. 2.If tagraxofusp is recommended, will I be admitted to the hospital for my first cycle to monitor for side effects?
  3. 3.How many doses of intrathecal therapy (CNS prophylaxis) will I need during my treatment?
  4. 4.Am I considered an eligible candidate for an allogeneic stem cell transplant given my age and overall health?
  5. 5.If I am not a candidate for transplant, what does my long-term maintenance therapy plan look like?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.

    Lee SS, McCue D, Pemmaraju N

    Expert review of anticancer therapy 2020; (20(7)):543-550 doi:10.1080/14737140.2020.1776120.

    PMID: 32460559
  2. 2

    Blastic Plasmacytoid Dendritic Cell Neoplasm.

    Jain A, Sweet K

    Journal of the National Comprehensive Cancer Network : JNCCN 2023; (21(5)):515-521 doi:10.6004/jnccn.2023.7026.

    PMID: 37156483
  3. 3

    Blastic plasmacytoid dendritic cell neoplasm: diagnosis, manifestations, and treatment.

    Sweet K

    Current opinion in hematology 2020; (27(2)):103-107 doi:10.1097/MOH.0000000000000569.

    PMID: 31972688
  4. 4

    Targeting CD123 in AML.

    Lane AA

    Clinical lymphoma, myeloma & leukemia 2020; (20 Suppl 1()):S67-S68 doi:10.1016/S2152-2650(20)30466-3.

    PMID: 32862874
  5. 5

    Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report and Clinicopathological Review.

    Zaki MMAF, Zalata K, El-Hawary AK, et al.

    Journal of hematology 2018; (7(3)):124-127 doi:10.14740/jh428w.

    PMID: 32300426
  6. 6

    Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review.

    Abla D, Abboud MR, Noun D, et al.

    Leukemia research reports 2022; (17()):100313 doi:10.1016/j.lrr.2022.100313.

    PMID: 35462725
  7. 7

    Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD.

    Pemmaraju N, Wilson NR, Garcia-Manero G, et al.

    Blood advances 2022; (6(10)):3027-3035 doi:10.1182/bloodadvances.2021006645.

    PMID: 35061885
  8. 8

    [Blastic plasmacytoid dendritic cell neoplasm with complete clinical remission with chemotherapy and central nervous system relapse: Report of one case].

    Contreras L, Mercado L, Delgado C, et al.

    Revista medica de Chile 2017; (145(1)):115-120 doi:10.4067/S0034-98872017000100015.

    PMID: 28393977
  9. 9

    Blastic Plasmacytoid Dendritic Cell Neoplasm With Central Nervous System Involvement: A Case Report.

    Molina Castro D, Perilla Suárez O, Cuervo-Sierra J, Moreno A

    Cureus 2022; (14(4)):e23888 doi:10.7759/cureus.23888.

    PMID: 35530883
  10. 10

    Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant.

    Yun S, Chan O, Kerr D, et al.

    Blood advances 2020; (4(14)):3435-3442 doi:10.1182/bloodadvances.2020001875.

    PMID: 32722779
  11. 11

    Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

    Bashir Q, Milton DR, Popat UR, et al.

    Bone marrow transplantation 2022; (57(1)):51-56 doi:10.1038/s41409-021-01478-5.

    PMID: 34629467
  12. 12

    Real-world evidence on tagraxofusp for blastic plasmacytoid dendritic cell neoplasm - collected cases from a single center and case reports.

    Faustmann P, Schroeder JC, Mix L, et al.

    Frontiers in oncology 2024; (14()):1384172 doi:10.3389/fonc.2024.1384172.

    PMID: 38665943
  13. 13

    [Chemotherapy Combined with Venetoclax Followed by Allo-Hematopoietic Stem Cell Transplantation for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm].

    Cheng P, Wang LL, Wang QX, et al.

    Zhongguo shi yan xue ye xue za zhi 2023; (31(5)):1531-1536 doi:10.19746/j.cnki.issn.1009-2137.2023.05.044.

    PMID: 37846712
  14. 14

    Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report.

    Zheng JX, Betts EV, Dwyre DM, et al.

    Clinical pathology (Thousand Oaks, Ventura County, Calif.) 2024; (17()):2632010X241304564 doi:10.1177/2632010X241304564.

    PMID: 39687328
  15. 15

    Venetoclax combined with azacitidine for treatment of a blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.

    Lai Y, Chen X, Zhou H

    Experimental and therapeutic medicine 2026; (31(1)):20 doi:10.3892/etm.2025.13015.

    PMID: 41282467

This page explains BPDCN treatment options for educational purposes only. Always consult your oncologist or hematologist to determine the best treatment plan for your specific diagnosis.

Get notified when new evidence is published on Blastic plasmacytoid dendritic cell neoplasm.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.